Testosterone does not directly cause acid reflux, and no randomized trial has shown that replacement therapy raises GERD rates. It can worsen reflux indirectly in a minority of men through three routes: fluid and weight gain in the first months, worsening obstructive sleep apnea, and supraphysiologic doses taken outside medical supervision. Men on standard replacement doses who keep a waist under 40 inches generally report no change in heartburn. Bodybuilders using 3 to 10 times the replacement dose, and men with untreated sleep apnea, carry the plausible risk. The honest answer is that the mechanism is indirect, the evidence is observational, and the effect size is modest.
Mechanisms: How Testosterone Could Reach the Esophagus
The esophagus is not a classic androgen target, but androgen receptors are detectable in esophageal squamous epithelium and in the muscularis propria. Whether those receptors sit on human lower esophageal sphincter (LES) smooth muscle is unsettled. Steroid hormones act on gut muscle in two time frames: non-genomic effects within minutes, and genomic effects over hours to days. Progesterone is the established relaxant of this valve. Testosterone is not.
Healthy LES resting pressure runs 10 to 30 mmHg. A resting pressure below 6 mmHg is strongly associated with reflux. Transient LES relaxations, abrupt vagally mediated drops lasting 10 to 45 seconds, account for 60 to 80 percent of reflux episodes in healthy adults. These relaxations are mediated by nitric oxide and vasoactive intestinal peptide. No study has shown that testosterone alters that nitric oxide signaling in the sphincter.
The first indirect route is intra-abdominal pressure. Obesity roughly doubles the odds of reflux symptoms compared with normal weight, per the 2005 Hampel meta-analysis, and waist circumference outperforms body mass index as a predictor. Testosterone replacement adds 2 to 4 kg of lean mass and can add 0.5 to 2 kg of water weight early on. That is enough to change how a waistband fits, though not enough to recreate the pressure load of visceral obesity.
The second route is sleep apnea, and it is the most mechanistically convincing one. Testosterone therapy can worsen obstructive sleep apnea in men who already have it, partly by shifting ventilatory control. During an apnea, the diaphragm pulls against a closed airway and generates negative intrathoracic pressure swings of roughly −40 to −60 cm H2O. That suction reduces the pressure gradient holding the sphincter closed. GERD prevalence in sleep apnea patients runs 50 to 60 percent, against roughly 20 percent in the general adult population.
The third route is aromatization. Adipose tissue converts testosterone to estradiol, so men with more body fat generate more estradiol per milligram of testosterone. Estradiol's net effect on the male sphincter is not established, and the women's hormone therapy literature is mixed. Aromatization is a real pathway with an unknown destination.
In plain terms: testosterone probably does not touch the valve directly. It changes the pressure around the valve and the sleep that regulates it.
Can Testosterone Cause Acid Reflux? The Evidence
No randomized controlled trial has ever tested reflux as an endpoint in men taking testosterone. The Testosterone Trials enrolled 790 men aged 65 and older and were powered for anemia, bone density, and sexual function. TRAVERSE randomized 5,246 men with hypogonadism and cardiovascular risk, and its primary outcome was major cardiac events. Neither trial published a reflux analysis, and neither was built to detect one.
What exists instead is indirect evidence. About 18 to 28 percent of North American adults have weekly reflux symptoms, per the 2022 ACG guideline. Men report slightly fewer symptoms than women but carry roughly twice the rate of erosive esophagitis. They carry 3 to 8 times the rate of Barrett's esophagus and about 7 times the rate of esophageal adenocarcinoma.
That male predominance is one of the largest unexplained sex disparities in gastroenterology. Androgen receptor signaling in Barrett's epithelium is one hypothesis for cancer promotion. Note carefully what that hypothesis claims: it is about progression of damaged tissue, not about generating reflux in the first place. Those are different questions with different evidence.
The confounding problem is severe. Between 40 and 50 percent of men with hypogonadism meet criteria for metabolic syndrome, against roughly 25 percent of eugonadal men. A man who presents with both low testosterone and heartburn usually has one shared upstream driver: visceral fat. Testosterone normalizes, reflux persists, and the patient attributes the heartburn to the new medication.
Dose separates the plausible from the implausible. Standard replacement runs 50 to 100 mg of injectable ester weekly or 40 to 100 mg of transdermal gel daily, producing serum levels of 400 to 800 ng/dL. Recreational and performance doses run 300 to 600 mg weekly, producing 1,500 to 3,000 ng/dL or more. That is a 3- to 10-fold difference in exposure, and it is the range where almost all anecdotal reflux reports originate.
Testosterone, Estrogen, and Progesterone Compared
| Hormone and context | Typical serum level | Effect on LES pressure | Reflux association | Strength of evidence |
|---|---|---|---|---|
| Testosterone, replacement dose | 400-800 ng/dL | None established | No consistent signal | Weak, observational |
| Testosterone, supraphysiologic | 1,500-3,000 ng/dL | Never measured in humans | Anecdotal reports only | Very weak |
| Estradiol, men on TRT | 20-40 pg/mL | No consistent effect | Mixed | Weak |
| Progesterone, third trimester | 100-300 ng/mL | Falls 20-40 percent | 30-50 percent of pregnancies, up to 70 percent by trimester three | Strong |
| Combined estrogen-progestin therapy | Variable | Modest reduction | Inconsistent across trials | Moderate |
Lab values above use conventional reporting units, not body measurements. The table makes one point sharply: the hormone with a quantified sphincter effect is progesterone, and the effect is large. Testosterone sits in the column marked "unmeasured," which is a statement about the literature, not about safety.
Progesterone relaxes the sphincter through reduced smooth muscle sensitivity to acetylcholine and increased nitric oxide activity. That mechanism is well mapped and dose-dependent. Anyone who assumes testosterone behaves the same way is extrapolating from a different molecule with a different receptor.
A TRT Timeline for Reflux Symptoms
| Time after first dose | Physiological change | Reflux relevance |
|---|---|---|
| 0-48 hours | Transdermal gel reaches steady state; injectable esters begin releasing | None measurable |
| Days 2-14 | Sodium and water retention; +0.5 to 2 kg water weight; ankle edema in 5-10 percent | Waistband tightens; sphincter unchanged |
| Weeks 2-6 | Ventilatory drive shifts; existing sleep apnea may worsen | Nocturnal reflux risk rises in men with apnea |
| Months 1-3 | Hematocrit climbs 1-3 percentage points; libido and energy improve | No direct esophageal effect |
| Months 3-6 | Lean mass +2-4 kg, fat mass −1-3 kg, waist −1-3 cm | Reflux often improves if visceral fat falls |
| Months 6-12 | Body composition plateaus; erythrocytosis in 5-15 percent | Net effect tracks waist circumference |
| Year 2 onward | Stable if dose is stable | Outcome depends on weight maintenance |
Three thresholds get confused constantly, and they measure different things. Forty inches is the waist circumference above which reflux risk climbs in men, 300 ng/dL is the lower bound of the normal testosterone range, and 54 percent is the hematocrit at which the 2018 Endocrine Society guideline advises stopping therapy and evaluating for hypoxia or sleep apnea. Only the first one is about reflux.
The timeline carries a practical implication. If heartburn appears in the first two weeks of therapy, fluid retention and dietary change are the likely culprits, not the hormone acting on the sphincter. If it appears at week six alongside louder snoring, order a sleep study before touching the dose.
Edge Cases and Corrected Misconceptions
Bodybuilders are the least studied and most exposed group. Surveys of anabolic-androgenic steroid users document dyslipidemia, elevated liver enzymes, and hypertension, but no registry tracks reflux. Oral 17-alpha-alkylated agents such as oxandrolone add hepatotoxicity on top of the androgen load. The reflux reports in this population are anecdotal, and the confounders, including high-calorie bulking diets and pre-workout stimulants, are enormous.
Transgender men on testosterone represent a second gap. No published cohort has measured GERD incidence in this group. Chest binding, common in this population, compresses the torso and plausibly raises intra-abdominal pressure, but that remains hypothesis rather than finding.
The first misconception is that testosterone is "a steroid like prednisone." It is not. Anabolic-androgenic steroids and glucocorticoids act on different receptors with different tissue effects. Glucocorticoids carry a modest peptic ulcer association, mostly when combined with NSAIDs, and that risk is about mucosal injury rather than reflux. The confusion costs patients accurate information.
The second misconception is that testosterone relaxes smooth muscle the way progesterone does. Progesterone's effect is quantified and dose-dependent. Testosterone's is unmeasured. Repeating the progesterone finding as if it transferred is a category error dressed as physiology.
The third misconception is that TRT causes weight gain that worsens reflux. The opposite often happens over six to twelve months: fat mass falls by 1 to 3 kg while lean mass rises. Early water weight is transient. Judging reflux risk at week two and never rechecking is the actual error.
What to Actually Do
Keep total testosterone in the mid-normal range, roughly 400 to 700 ng/dL, rather than at the top of the reference range. Dose escalation beyond replacement has no established benefit for reflux and adds erythrocytosis and apnea risk. Measure waist circumference at the navel every three months; 40 inches is the line that matters.
Screen for sleep apnea before starting therapy if body mass index exceeds 30 and snoring is present. Treating apnea frequently reduces nocturnal reflux on its own. Elevate the head of the bed 6 to 8 inches and stop eating within three hours of lying down, which are the two highest-yield positional measures in the ACG guideline.
If reflux worsens within four to eight weeks of starting therapy, log the timing against dose and against body weight. Bring that log to the prescriber rather than stopping the medication unilaterally. Weight loss of 5 to 10 percent of body weight reduces reflux symptoms substantially and outperforms any dose adjustment.
Seek evaluation promptly for any of the following:
- Difficulty swallowing or food sticking at the breastbone
- Unintentional weight loss exceeding 5 percent in six months
- Black stools, vomiting blood, or unexplained iron deficiency
- Chest pressure radiating to the jaw or arm, or pain brought on by exertion
- New anemia with hemoglobin below 13 g/dL in a man
- Nighttime choking, coughing fits, or hoarseness lasting weeks
Limits of the Evidence
The central limitation is statistical power. Detecting a 25 percent relative increase in reflux, from a 20 percent baseline to 25 percent, with 80 percent power and a two-sided alpha of 0.05 would require roughly 1,100 men per arm. No testosterone trial has come close to that for a reflux endpoint, and none is planned.
Symptom reporting introduces a second bias. Men underreport heartburn relative to objective esophageal findings, which is exactly why erosive esophagitis and Barrett's rates are higher in men than their symptom rates predict. A trial relying on questionnaires would systematically underestimate the outcome it was built to detect.
Confounding by indication is the third limit. Testosterone is prescribed to men who are disproportionately obese, diabetic, and apneic, and all three conditions independently cause reflux. Untangling the drug from the diagnosis would require randomization against a background of identical metabolic risk, which no existing dataset provides.
The final gap is dose. Replacement physiology and supraphysiologic exposure are different experiments, and only the first has been run under controlled conditions. Any confident claim that testosterone causes or prevents reflux is going beyond what the data support in either direction.